A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPERA II; ORCHESTRA
  • Sponsors Roche
  • Most Recent Events

    • 12 Oct 2017 Results of OPERA I and OPERA II assessing disease activity measures and patient characteristics on Health utilities in patients with relapsing multiple sclerosis, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Oct 2017 Results of this trial and another one (refer CTP: 191566) assessing efficacy in terms of progression over Extended Disability Status Scale (EDSS) states were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 15 Aug 2017 Health Canada has approved OCREVUS for RRMS. This approval is based on the pivotal OPERA I and II studies, according to a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top